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Clinical Thermoradiotherapy
HI Bicher, MD, PhD,* TS Sandhu, PhD,* and FW Hetzel, PhD^

A clinical trial is currently in progress to determine the
efficacy of combined fractions of hyperthermia and radiation. The protocol consists of two parts. First, four fractions
of microwave-induced
hyperthermia (45.0° ± 0.5°C) are
applied for 1V2 hours to the volume encompassing the
tumor, each separated by 72 hours. After a one-week rest, a
second series of four fractions is administered again at 72hour intervals. Each fraction consists of a 400 rad dose of
radiation followed within 20 minutes by hyperthermia
(42.5 ± 0.5°C) for V/2 hours.

Currently, we have treated 62 patients with 82 fields with a
mean follow-up time of six months to date. Total regression
was observed in 60% of all cases, and partial regression in
33%; no response was seen in only 6% of all those treated.
Eive local and three marginal recurrences have been observed. This paper discusses details of response based on
site, histology, and classification.

The failure of conventional radiotherapy to control a
significant number of tumors without any extensive adverse
effects on the surrounding normal tissue is mainly attributed to the presence of a viable hypoxic fraction of cells
in these tumors. As far back as 1909 Schwarz (1) showed
that if blood circulation was restricted by limiting oxygen
supply, human skin become radioresistant. Because o f t h e
heterogeneous structure of tumors in general, there are
regions containing closely packed cells, remote from blood
vessels, that are hypoxic (2). If even avery small fraction of
hypoxic cells exists, radiotherapy will not be able to control the tumor.

rence. Even a few hypoxic cells would constitute a serious
problem. To compensate for this limitation, one solution
has been to use high linear energy transfer (LET) radiation
instead of ordinary x- and y-rays, so that the tumor response does not depend on the presence or absence of
molecular oxygen. The ideal radiation that will have oxygen enhancement (OER) of unity, such as IMeWa particles,
is incapable of penetrating tissue deeply enough to be
useful. The best that can be achieved is through the use of
neutrons, pions, or high-energy heavy ions. These options
tend to be very expensive, and limited clinical trials are still
going on.

To overcome this problem, many different approaches
have been tried. One early solution was to give the total
radiation doses in several fractions. During the course of
fractionated treatments, the resistant hypoxic cells become
oxygen sensitive, at least during later doses. However, it is
possible that some tumors do not reoxygenate completely
so that some hypoxic cells still survive and cause a recur-

In another approach, the patient is placed in an environment of pure oxygen at a pressure of 2 to 3 atmospheres
before radiotherapy begins in an attempt to increase the
availability of oxygen to tumors. This technique has not
produced any significant improvement in tumor control,
although a few centers around the world are still conducting clinical trials.
In recent years there has been increasing interest in hyperthermia to treat cancer, used efther alone or in combination
with radiation. Although reports on its use date back to
1866 (3), research on hyperthermia has been stimulated in
the past two decades by several interesting findings in
thermoradiobiological studies.

* Radiobiology Division, Department of Therapeutic Radiology, Henry
Ford Hospital
Address reprint requests to Dr. Bicher, Radiobiological Sciences, Department of Therapeutic Radiology, Henry Ford Hospital, 2799 W Grand Blvd,
Detroit, M l 48202
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temperatures to which tumors and surrounding normal
tissues were heated. This imprecision, along with the lack
of radiation controls alone, makes ft very difficult to draw
any quantitative conclusions or even to establish that tumor
temperature was raised at all.

Rationale
Recent, extensive radiobiological and limited clinical studies show that hyperthermia combined with radiation has a
synergistic cell-killing effect. Both in vitro (3-6) and in vivo
(7-11) studies show that thermal enhancement depends not
only on the sequence ofthe two treatments, but also on cell
cycle effects. The synergistic effect is most pronounced for
radioresistant S-phase cells (12,2). Clinically, the most important observation is that the h y p o x i c cells may be
equally or more sensitive to hyperthermia than aerobic
cells (3,10,13,14). The rationale for using hyperthermia
above 43°C in combination with ionizing radiation is that
the viable hypoxic tumor cells, which are radioresistant,
will be destroyed at these temperatures. Mild hyperthermia
(40°-42°) also introduces a significant change in tumor
blood flow. It has been shown both in mouse tumor studies
and in clinical trials (15) that hyperthermia in the 40°-42°C
range increases the blood flow with a concomitant increase
in oxygenation, ft will effectively sensitize the otherwise
radioresistant h y p o x i c cells in the tumor. Dramatic
changes in cell survival during hyperthermia have also
been observed when the pH of cells is only slightly altered
(16). Although there are no in vitro data to indicate differential response or sensftization of tumor cells as opposed to
normal tissue cells, the cellular environment in the two
cases is expected to be quite different in vivo. For example,
several studies (17-20) indicate that the pH of fluid in
human and rodent solid tumors is lower than the normal
pH of 7.4. This will result in differential tumor cell killing
that spares normal tissue. Other studies (21,22) show that
some tumors have a sluggish blood flow as compared to
normal tissue. This finding suggests that under similar
heating conditions tumors are not able to dissipate heat as
efficiently as the normal tissue. These findings about the
different microenvironments in tumors and normal tissue
regarding pH, blood flow, and nutritional state probably led
earlier investigators (23-26) to conclude that hyperthermia
selectively killed the tumor cells.

The earliest reported combination of hyperthermia and
ionizing radiation is that of Schmidt (30) in 1909. He
proposed to treat malignancies by using diathermy for
localized heating of tissue in combination with ionizing
radiation. Some years later, Arons and Sokoloff (31) used
radiofrequency (RF) currents for hyperthermic treatments of
intrathoracic and intra-abdominal tumors. However, since
they made no temperature measurements, it is difficult to
establish whether they were able to raise the tissue temperature to a therapeutic range. Woeber (32) used ultrasound with simultaneous x-irradiation to treat 20 patients
wfth cutaneous malignancies. He reported that tumors
could be controlled with a 40% reduction in radiation dose
and that reactions of normal tissues were also diminished.
Crockett, et al (33), following some experimental work on
normal dog bladders, treated seven elderly patients who
had incurable advanced bladder carcinomas wfth a combination of local hyperthermia and regional radiotherapy.
The radiation dose varied from 4500 to 5500 rad. These
authors reported that the treatment produced a striking
reduction in tumor size without any serious adverse effects.
Although they suggested that hyperthermia enhanced the
tumor response, they did not attempt to determine heat
distribution within the bladder. Recently, Hall (34) also
reported regression of bladder papillomatosis without any
complications. Each patient's bladder was irrigated for
three hours at a time wfth water heated to 42°-45°C for 5-14
sessions.
Hartman and Crile (35) treated osteogenic sarcoma in five
children with microwave heating and various doses of
radiation. Two of the five were alive five years later and
were still able to use their limbs. One was a seven-year-old
girl with osteogenic sarcoma in the right mid-tibia, and the
other was a 16-year-old with osteoblastic and osteolytic
lesions of the metaphysis of the distal part of the left radius.
The other three children survived six to 17 months and died
of metastatic disease.

Based on the above in vitro and in vivo radiobiological
findings, several groups of investigators (15,21,25,27-29)
are using a combination of hyperthermia and ionizing
radiation in clinical studies. The clinical goals, methodology, and results of some of these studies are discussed in
the following section.

Stehlin (36) reported a 67% five-year survival rate for 32
patients he treated by using heated blood to perfuse the
extremities, followed by x-irradiation several weeks later.
He found that at tissue temperatures of 40°C patients
tolerated the treatment very well for several hours, but
when the extremities were perfused with blood heated to
46°C, complications resulted.

Clinical Thermoradiotherapy
Clinical applications of combined hyperthermia and radiation treatment date back to the beginning of tbe century,
but early reports are anecdotal. Most reported only an
attempt to treat human tumors and did not document the

In the past few years several prospective clinical trials have
been started. We are reporting the results ofthe Henry Ford
Hospital trial.
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Materials and Methods

partially filled rectangular waveguide excited in the TEM
mode. The second applicator distributes heat better than
the first one. Thermometry was accomplished by inserting
one or two ultramicrothermocouples* in the tumor tissue,
depending upon the size and location.

In this study we designed a fractionation scheme that
combined hyperthermia and radiation with a curative intent. The protocol is summarized below.
1. Hyperthermia only: 4 treatments at 45°C for 90 minutes (skin 36°C or below), at 72-hour intervals;

Results

2. Rest one week; response to heat alone evaluated;

To date, 62 patients have been treated with 82 fields
(Tables I and II). A total response was observed in 49
treatment fields, a partial response in 27, and no response
in only 6 fields. These included one each of squamous cell
carcinoma, adenocarcinoma, and sarcoma. The only complications that could be directly attributed to treatment

3. Radiation therapy and hyperthermia: 4 treatments at
42°C for 90 minutes; heat follows radiation (20minute intervals); RT: 400 rad fractions for each
treatment;
Total: 8 hyperthermia treatments -h 1600 rad/2 weeks/4
fractions.

TABLE I
Treatment Results

This protocol has been designed to take advantage o f t h e
known effects of hyperthermia either alone or combined
with radiation. Skin cooling was implemented to prevent
normal tissue damage. We chose the number of fractions
and duration of each treatment at random, taking into
account such factors as the patient's compliance and comfort and possible b i o l o g i c a l factors such as thermotolerance, vascular response, and repair. In addition,
the total dose of radiation was low enough to allow previously irradiated areas to be treated more than once.

82 Fields Treated

62 patients

Total Response

49 (60%)

Partial Response

27 (33%)

No Response

6 ( 7%)

Recurrence

Localized hyperthermia was induced in all patients by
microwave radiation that used direct contact applicators
(37). The tumor size, location, and depth determine the
exact type and size of applicator to be used as well as the
microwave frequency (915 or 300 MHz).* Heat is initially
applied to the tumor in four fractions of 116 hours each at
72-hour intervals. The temperature is monitored with conventional (Bailey) or ultramicrothermocouples (Medtra Inc)
to maintain the tumor temperature at 45°C ± 0.5°C, while
the overlying, normal skin is simultaneously air cooled at
or below 36°C. After these four fractions have been applied, the patient rests for one week and then receives four
more fractions of hyperthermia, this time in combination
with radiation. Each of these four treatments consists of
doses of 400 rad to the tumor followed immediately (20
minutes) by hyperthermia at a temperature of 42.0° ±
0.5°C, again at 72-hour intervals. As before, skin cooling is
used to maintain a temperature of 36°C or lower at the
surface.

Local:

5

Marginal:

3

Complications
Skin burns:

2 (completely healed)

Tongue and pharynx burns

2 (completely healed)

Grand seizure:

1 (epileptic patient)
TABLE II

Histology
Malignant melanoma

17

Malignant lymphoma

8

Response

Follow-up

8 Total
6 Partial
3 No response

2 mo-1 yr

8 Total

2-7 mo

Squamous cell carcinoma

19

7 Total
11 Partial
1 No response

2-6 mo

Adenocarcinoma

33

24 Total
8 Partial
1 No response

2-7 mo

other (transitional cell,
basal cell, glioma, sarcoma
Summary

The microwave hyperthermia was induced with direct
contact applicators, which are essentially square or rectangular cross-section waveguides.* We used two types of
microwave applicators: 1) a square or rectangular crosssection waveguide completely loaded with a low-loss dielectric material and excited in TEio mode (37); 2) a

No. of
Fields

5
82

2 Total
3 Partial
49 Total
27 Partial
6 No response

2-9 mo
2 mo-1 yr

Total Response: No tumor at two months' follow-up and thereafter.
Partial Response: Tumor decreased in size to half or less at two months'
follow-up.

* All equipment by Medtra Inc, Detroit, M l
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were two skin burns caused by inadequate surface cooling
and two tongue and pharynx burns; all healed completely.
One patient with a history of epilepsy experienced a grarid
mal seizure when being treated for a neck tumor. Three
marginal recurrences and five local recurrences have been
noted. Although it should be emphasized that great care is
needed during the initial planning and set-up for the patient, it is possible to obtain actual thermometry for every
treatment of every field with minimal patient discomfort.

was a great variation in both the radiation dose and the
length of hyperthermia treatment as well as in the number
of fractions. The radiation doses varied from 800 rad in two
fractions for melanoma to 2400 rad in eight fractions for
Karposi sarcoma. Similarly, hyperthermia (43.5°C) treatments varied from t w o fractions of 30 minutes for
melanoma to 5 fractions of 60 minutes for mycosis
fungoides. The hyperthermia treatments immediately followed the radiation treatments in all cases. While these
data do not suggest any particular treatment schedule for a
particular tumor, they do demonstrate the greater effectiveness of combined thermoradiotherapy as compared to
hyperthermia or radiation alone.

Table II summarizes histological results. Among our patients, malignant lymphoma was most responsive to this
combination treatment. It should be pointed out that tumor
regression after treatment ends is very slow and requires
approximately two months before the total effect is observed. We also discovered during these treatments that the
microwave power required to maintain the desired treatment temperatures declines after the first or second treatment of a given field. These two phenomena are probably
related to heat-induced physiological changes within the
tumor that affect its ultimate destruction. Further physiological studies are currently in progress.

Hornback, et al (27) used the combined therapy to treat 72
patients who had advanced cancer. Of those treated wfth
hyperthermia before radiation therapy, 53% experienced
complete remission of symptoms, while of those treated
with heat following radiotherapy, 92% showed complete
remission. Again, there was no set protocol and the radiation doses varied from 50 to 600 rad per day, with total
doses from 3000 to 6500 rad. Heat treatments used 433.92
MHz microwaves. Although the authors mention that they
attempted to measure tumor temperature during these
treatments, tumor temperatures in the patients are not
given.

Another interesting outcome of this study concerns the
possible significance of the three marginal recurrences;
they may indicate that this combined modality effectively
treats microscopic disease. More time is needed for followup, and more patients must be treated before the clinical
efficacy ofthis protocol can be fully evaluated.

Johnson, et al (28) conducted a pilot study to evaluate
normal skin and melanoma tumor thermal enhancement
ratios of 41.5°-42°C hyperthermia with radiation. They
measured the response of normal skin to treatment by
evaluating the degree of erythema according to a numerical scoring system. Tumor response was assessed by measuring t u m o r diameter. A l t h o u g h the study was not
conclusive about the thermal enhancement ratio, it did
highlight some of the problems in obtaining useful clinical
data.

Discussion
Recent studies (15,21,25,27,28,38,39) involving a combination of hyperthermia and x-irradiation have attempted
to measure and document hyperthermia treatments more
accurately. In most cases, these studies compared their
treatment methods with radiation controls alone. Kim, et al
(25) treated 50 patients who had a variety of cutaneous
tumors. They reported improved results for both the radiosensitive (i.e., mycosis fungoides) and radioresistant
(i.e., melanoma) tumors with the combined hyperthermia
and radiation treatment as compared to either modality
used alone. Their overall tumor control rate was 78% after
combined therapy as compared with 26% after radiation
alone. Multiple recurrent melanoma nodules completely
disappeared without unusual normal skin reactions. However, combination therapy did intensify skin reactions in
patients whose treated areas included either a skin graft or
heavily scarred skin from extensive surgery.

The study involved patients w i t h m u l t i p l e metastatic
melanoma lesions. At least three lesions were chosen on
each patient, all of whom were divided into three groups
and given one, three, or four fractions, with a minimum 72hour interval between each fraction. Radiation dose per
fraction for different lesions varied from 500 to 900 rad. In
some cases, they used single fractions of 1000, 1100, 1200,
or 1300 rad. In all patients one lesion was heated immediately after radiation therapy, and was then used for comparison with other lesions treated with radiation alone.
Hyperthermia treatments, which varied between 1 and 2
hours at 41.5°-42°C, were administered with 915 MHz
direct contact microwave applicators (37).

These investigators used two heating methods. Some patients with tumors on extremities were heated by immersion in waterbath, while the rest ofthe patients were treated
wfth RF (27.12 MHz) inductive heating. In their study, there

Because of the lack of follow-up data, skin enhancement
ratio (SER) and tumor enhancement ratio (TER) could be
evaluated for only a few patients. SER values varied from
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1.2 to 1.7, while TER values in most cases were 1.3. This
study demonstrated, however, that superficial tumors of up
to 4 cm wide and 2 cm deep could be heated wfth an
accuracy of ± 0.5°C efther during or after radiation with
915 MHz microwaves.

u p t o a total of 4000/7000 rad. All lesions were irradiated
with the same total dose, whether or not they received
hyperthermia.
The MDF schedule resulted in a 46% complete response,
which was enhanced to 85% complete response when
combined with hyperthermia; the remaining 15% showed
partial response. It should be noted that when MDF was
combined wfth hyperthermia, heat was applied immediately after the second daily fraction. The authors did not
observe any abnormal reactions in areas that received the
combined treatment.

Manning, et al (29) reported on a very limited study that
combined heat and radiation. Of 40 patients treated with
hyperthermia, four were treated in combination with radiation. Each had a minimum of three nodules. One nodule
received a heat treatment of 43°C for 40 minutes with
radio-frequency currents. Another nodule received radiation alone from two radium needles to a dose of 4000 rad
in 100 hours. A third lesion received the same dose in
addftion to heat to 43°C for 40 minutes simultaneously,
with radium needles used as heating electrodes.

In the study reported here, we have obtained an overall
total response rate of 60%. Although further study and
follow-up are necessary and other protocols must be examined, it is clear from these results that regardless of anatomical location and tumor histology, hyperthermia appears to
be an effective modality to treat malignant disease.

The response rate for the heat-radiation combination was
80-90% compared with a 50% response rate for heat alone
and radiation alone. These authors suggest a beneficial
therapeutic ratio and minimal side effects from the combined treatment.
Another limited study (39) treated two groups of patients
either with radiotherapy alone, hyperthermia alone, or
combined treatment. One group received 200-600 rad
fractions, 2-5 times per week for a total of 1800-4200 rad
in 5-14 fractions. The other group received combined
thermoradiotherapy treatments only, radiation fractions of
200-600 rad, 2-5 times a week, for a total of 2000-4800 rad
in 6-20 fractions. Both groups received hyperthermic treatments (42-44°C) 2-3 times per week to a maximum of 10
sessions in 4 weeks. Either 2450 or 915 MHz microwaves
were used for the treatments. In tbe first group of eight
patients, lesions in six patients regressed completely after
they were treated with radiation and hyperthermia within
one month of therapy. None of the tumors treated with
hyperthermia alone regressed completely. In the second
group of patients, 73% showed tumor regression.
Melanoma regressed completely in two of four cases. No
adverse side effects on normal tissue were observed from
the combined treatments.
Arcangeli, et al (21) reported that 15 patients with multiple
neck node metastases from head and neck were treated
either with radiation alone or radiation combined with
hyperthermia. A total of 33 neck nodes were treated, 12
with radiation alone, and 21 with the combination. Hyperthermia was induced by 500 MHz microwaves with a noncontact applicator.
These investigators used a very interesting fractional
scheme. Described as a multiple daily fractional (MDF)
scheme, it consists of 200 4- 150 -1- 150 rad/day, with 4-5
hour intervals between fractions, for 5 days per week, and
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